When to Give and When to Pivot: BCMA-Targeted Therapies and Care Models in Late-Relapsed Multiple Myeloma

Meeting Objectives:

• • Evaluate when to rechallenge with BCMA-targeted therapy versus transition to alternative bispecific mechanisms in later-line disease, accounting for evolving earlier use of BCMA agents.
  • Recommend effective referral and care transition protocols between academic and community settings, including bispecific administration pathways and safety monitoring. 
  • Apply sequencing and care coordination principles to real-world myeloma cases and synthesize evidence-based treatment recommendations.